{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:50:52Z","timestamp":1791334252954,"version":"4.3.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Genentech, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced liver injury (DILI) remains a major cause of preclinical and clinical attrition, reflecting persistent gaps in the predictive translation of preclinical safety data to human outcomes. To address these gaps, we established a refined multiparametric framework for early DILI risk prediction using a balanced reference set of 170 drugs with established clinical outcomes. Thirty physicochemical, mechanistic endpoints, and exposure-related features were systematically evaluated to identify high-specificity predictors of intrinsic DILI risk. Cytotoxicity in primary human hepatocytes and human liver microtissues, mitochondrial toxicity (i.e. mitotoxicity), and bile salt export pump inhibition were identified as top predictive features. Incorporation of clinical exposure data to derive margins of safety substantially improved assay performance, emphasizing the importance of exposure normalization. A multiparametric, flag-based hazard framework integrating \u22652 hazard flags achieved 98% specificity and a positive likelihood ratio of 18, providing a pragmatic approach for early compound triage and confidence in early decision-making. Random Forest models further enhanced predictive performance, identifying exposure, predicted lipophilicity (e.g. cLogD), mitotoxicity, cytotoxicity, and hepatic clearance as major contributors to DILI risk, with exposure-informed models achieving a balanced accuracy of 0.72. Application of the framework to contemporary Genentech portfolio molecules demonstrated translational utility in refining risk categorization, particularly for compounds with borderline or 0-1 hazard flags. Collectively, this work establishes a mechanistically informed and machine learning-enabled platform that combines interpretability, specificity, and practicality to guide safer molecule design in drug discovery and reduce hepatotoxicity-related attrition in clinical development.<\/jats:p>","DOI":"10.1093\/toxsci\/kfag124","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:40:53Z","timestamp":1790941253000},"source":"Crossref","is-referenced-by-count":0,"title":["A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development"],"prefix":"10.1093","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-2793","authenticated-orcid":false,"given":"Leah M","family":"Norona","sequence":"first","affiliation":[{"name":"Predictive Toxicology, Translational Safety, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-1376","authenticated-orcid":false,"given":"Fjodor","family":"Melnikov","sequence":"additional","affiliation":[{"name":"Predictive Toxicology, Translational Safety, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0862-6441","authenticated-orcid":false,"given":"Tomomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Predictive Toxicology, Translational Safety, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lawson","sequence":"additional","affiliation":[{"name":"Predictive Toxicology, Translational Safety, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-9288","authenticated-orcid":false,"given":"Cyrus","family":"Khojasteh","sequence":"additional","affiliation":[{"name":"Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4667-6555","authenticated-orcid":false,"given":"Joyce","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0479-4242","authenticated-orcid":false,"given":"Kevin","family":"Johnson","sequence":"additional","affiliation":[{"name":"Investigative ADME\/Toxicology & Bioanalytical Research Labs, Eli Lilly and Company , Indianapolis, IN 46285,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Pourmohamad","sequence":"additional","affiliation":[{"name":"Non-Clinical Biostatistics, Product Development, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart T","family":"Anger","sequence":"additional","affiliation":[{"name":"Predictive Toxicology, Translational Safety, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1567-7918","authenticated-orcid":false,"given":"William R","family":"Proctor","sequence":"additional","affiliation":[{"name":"Non-Clinical Safety, Preclinical Sciences, Research and Development, GlaxoSmithKline , Waltham, MA 02451,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9380-9419","authenticated-orcid":false,"given":"Aaron M","family":"Fullerton","sequence":"additional","affiliation":[{"name":"Predictive Toxicology, Translational Safety, Genentech, Inc , South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2026100620015268900_kfag124-B1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/hep.27206","article-title":"Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump","volume":"60","author":"Aleo","year":"2014","journal-title":"Hepatology"},{"key":"2026100620015268900_kfag124-B2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.therap.2018.02.004","article-title":"Safety data and withdrawal of hepatotoxic drugs","volume":"76","author":"Babai","year":"2021","journal-title":"Therapies"},{"key":"2026100620015268900_kfag124-B3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"Aaps J"},{"key":"2026100620015268900_kfag124-B4","doi-asserted-by":"publisher","first-page":"9860","DOI":"10.1038\/s41467-025-65690-3","article-title":"A large-scale human toxicogenomics resource for drug-induced liver injury prediction","volume":"16","author":"Bergen","year":"2025","journal-title":"Nat Commun"},{"key":"2026100620015268900_kfag124-B5","doi-asserted-by":"publisher","first-page":"e1484","DOI":"10.1002\/widm.1484","article-title":"Hyperparameter optimization: foundations, algorithms, best practices, and open challenges","volume":"13","author":"Bischl","year":"2023","journal-title":"Wiley Interdiscip Rev: Data Min Knowl Discov"},{"key":"2026100620015268900_kfag124-B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"2026100620015268900_kfag124-B7","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1002\/rcm.7062","article-title":"Post-acquisition analysis of untargeted accurate mass quadrupole time-of-flight MSE data for multiple collision-induced neutral losses and fragment ions of glutathione conjugates","volume":"28","author":"Brink","year":"2014","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2026100620015268900_kfag124-B8","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"2026100620015268900_kfag124-B9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"2026100620015268900_kfag124-B10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/toxsci\/kfx284","article-title":"Measures of BSEP inhibition in vitro are not useful predictors of DILI","volume":"162","author":"Chan","year":"2018","journal-title":"Toxicol Sci"},{"key":"2026100620015268900_kfag124-B11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/bmm.13.146","article-title":"Toward predictive models for drug-induced liver injury in humans: are we there yet?","volume":"8","author":"Chen","year":"2014","journal-title":"Biomark Med"},{"key":"2026100620015268900_kfag124-B12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"2026100620015268900_kfag124-B13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov Today"},{"key":"2026100620015268900_kfag124-B14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.xphs.2018.10.011","article-title":"Improving confidence in the determination of free fraction for highly bound drugs using bidirectional equilibrium dialysis","volume":"108","author":"Chen","year":"2019","journal-title":"J Pharm Sci"},{"key":"2026100620015268900_kfag124-B15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/b978-0-12-801415-8.00016-3","article-title":"Chapter sixteen analysis and interpretation of microplate-based oxygen consumption and pH data","volume":"547","author":"Divakaruni","year":"2014","journal-title":"Methods Enzym"},{"key":"2026100620015268900_kfag124-B16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.freeradbiomed.2011.08.005","article-title":"Assessing bioenergetic function in response to oxidative stress by metabolic profiling","volume":"51","author":"Dranka","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"2026100620015268900_kfag124-B17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human liver-chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun Medicine"},{"key":"2026100620015268900_kfag124-B18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/toxsci\/kft223","article-title":"A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans","volume":"137","author":"Gustafsson","year":"2014","journal-title":"Toxicol Sci"},{"key":"2026100620015268900_kfag124-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471140856.tx2304s54","article-title":"The vesicular transport assay: validated in vitro methods to study drug-mediated inhibition of canalicular efflux transporters ABCB11\/BSEP and ABCC2\/MRP2","volume":"54","author":"Her\u00e9di-Szab\u00f3","year":"2012","journal-title":"CP Toxicology"},{"key":"2026100620015268900_kfag124-B20","doi-asserted-by":"publisher","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"2026100620015268900_kfag124-B21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1021\/acs.chemrestox.6b00332","article-title":"Liabilities associated with the formation of \u201chard\u201d electrophiles in reactive metabolite trapping screens","volume":"30","author":"Kalgutkar","year":"2017","journal-title":"Chem Res Toxicol"},{"key":"2026100620015268900_kfag124-B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/jpet.114.220491","article-title":"Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists","volume":"352","author":"Kenna","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"2026100620015268900_kfag124-B23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/cpt.1222","article-title":"Can bile salt export pump inhibition testing in drug discovery and development reduce liver injury risk? An international transporter consortium perspective","volume":"104","author":"Kenna","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2026100620015268900_kfag124-B24","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug\u2013drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug\u2013drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res"},{"key":"2026100620015268900_kfag124-B25","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"2026100620015268900_kfag124-B26","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.21105\/joss.01903","article-title":"mlr3: a modern object-oriented machine learning framework in R","volume":"4","author":"Lang","year":"2019","journal-title":"J Open Source Softw"},{"key":"2026100620015268900_kfag124-B27","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA"},{"key":"2026100620015268900_kfag124-B28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/toxsci\/kfac054","article-title":"Early drug-induced liver injury risk screening: \u201cfree,\u201d as good as it gets","volume":"188","author":"Martin","year":"2022","journal-title":"Toxicol Sci"},{"key":"2026100620015268900_kfag124-B29","doi-asserted-by":"publisher","first-page":"e004221","DOI":"10.1136\/bmjopen-2013-004221","article-title":"An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making","volume":"4","author":"McNaughton","year":"2014","journal-title":"BMJ Open"},{"key":"2026100620015268900_kfag124-B30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3390\/ijms24010635","article-title":"Toward quantitative models in safety assessment: a case study to show impact of dose\u2013response inference on hERG inhibition models","volume":"24","author":"Melnikov","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026100620015268900_kfag124-B31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1021\/acs.chemrestox.3c00402","article-title":"Cyanide trapping of iminium ion reactive metabolites: implications for clinical hepatotoxicity","volume":"37","author":"Miao","year":"2024","journal-title":"Chem Res Toxicol"},{"key":"2026100620015268900_kfag124-B32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","article-title":"Current nonclinical testing paradigm enables safe entry to first-in-human clinical trials: the IQ consortium nonclinical to clinical translational database","volume":"334","author":"Monticello","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026100620015268900_kfag124-B33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol Sci"},{"key":"2026100620015268900_kfag124-B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/187231212800229309","article-title":"Evaluation of time-dependent cytochrome P450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach","volume":"6","author":"Mukadam","year":"2012","journal-title":"Drug Metab Lett"},{"key":"2026100620015268900_kfag124-B35","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1007\/s00204-020-02804-4","article-title":"In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk","volume":"94","author":"Norona","year":"2020","journal-title":"Arch Toxicol"},{"key":"2026100620015268900_kfag124-B36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"2026100620015268900_kfag124-B37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"2026100620015268900_kfag124-B38","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00204-017-2002-1","article-title":"Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury","volume":"91","author":"Proctor","year":"2017","journal-title":"Arch Toxicol"},{"key":"2026100620015268900_kfag124-B39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinform"},{"key":"2026100620015268900_kfag124-B40","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1021\/acs.chemrestox.5c00235","article-title":"Industry perspective on nonclinical approaches for hepatotoxicity risk assessment: insights from two longitudinal surveys conducted in 2023 and 2017","volume":"38","author":"Sakatis","year":"2025","journal-title":"Chem Res Toxicol"},{"key":"2026100620015268900_kfag124-B41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.tiv.2015.09.019","article-title":"Minimizing DILI risk in drug discovery: a screening tool for drug candidates","volume":"30","author":"Schadt","year":"2015","journal-title":"Toxicol In Vitro"},{"key":"2026100620015268900_kfag124-B42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/cld.388","article-title":"LiverTox: an online information resource and a site for case report submission on drug-induced liver injury","volume":"4","author":"Serrano","year":"2014","journal-title":"Clin Liver Dis"},{"key":"2026100620015268900_kfag124-B43","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/toxsci\/kfv152","article-title":"Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays","volume":"147","author":"Shah","year":"2015","journal-title":"Toxicol Sci"},{"key":"2026100620015268900_kfag124-B44","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/med.21273","article-title":"The generation, detection, and effects of reactive drug metabolites","volume":"33","author":"Stachulski","year":"2013","journal-title":"Med Res Rev"},{"key":"2026100620015268900_kfag124-B45","author":"Team RC","year":"2022"},{"key":"2026100620015268900_kfag124-B46","doi-asserted-by":"publisher","first-page":"730","DOI":"10.21037\/atm-2020-ubih-05","article-title":"Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues","volume":"9","author":"Teschke","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026100620015268900_kfag124-B47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17474124.2018.1383154","article-title":"The liver toxicity knowledge base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury","volume":"12","author":"Thakkar","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026100620015268900_kfag124-B48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/jat.3371","article-title":"A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk","volume":"37","author":"Tomida","year":"2017","journal-title":"J Appl Toxicol"},{"key":"2026100620015268900_kfag124-B49","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00204-020-02763-w","article-title":"The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development","volume":"94","author":"Walker","year":"2020","journal-title":"Arch Toxicol"},{"key":"2026100620015268900_kfag124-B50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41573-019-0048-x","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","author":"Weaver","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026100620015268900_kfag124-B51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1021\/acs.chemrestox.9b00264","article-title":"Predicting drug-induced liver injury with Bayesian machine learning","volume":"33","author":"Williams","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"2026100620015268900_kfag124-B1902716","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vascn.2016.10.006","article-title":"Harmonised high throughput microsomal stability assay","volume":"84","author":"Williamson","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2026100620015268900_kfag124-B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v077.i01","article-title":"Ranger\u202f: a fast implementation of random forests for high dimensional data in C++ and R","volume":"77","author":"Wright","year":"2017","journal-title":"J Stat Softw"},{"key":"2026100620015268900_kfag124-B53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/ elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"key":"2026100620015268900_kfag124-B54","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-1542-3","volume-title":"Cytochrome P450, in vitro methods and protocols","author":"Yan","year":"2021","edition":"1st"},{"key":"2026100620015268900_kfag124-B55","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1124\/dmd.113.056267","article-title":"High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2026100620015268900_kfag124-B56","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1021\/acs.chemrestox.0c00138","article-title":"Strategies to mitigate the bioactivation of aryl amines","volume":"33","author":"Zhang","year":"2020","journal-title":"Chem Res Toxicol"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfag124\/71581801\/kfag124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/209\/10\/kfag124\/71581801\/kfag124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/209\/10\/kfag124\/71581801\/kfag124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:02:00Z","timestamp":1791331320000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/doi\/10.1093\/toxsci\/kfag124\/8860756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfag124","relation":{},"ISSN":["1096-0929"],"issn-type":[{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]},"article-number":"kfag124"}}